Welcome to the TLDR Biotech newsletter!

TLDR Biotech aims to be your one-stop source for biotech and pharma updates - all with one daily email.

I’m always looking to make these news compilations more informative, impactful, and easy to navigate.

So if you have any feedback on what you like (or don’t), I’d love to hear from you! 📣

And if you like these newsletters and think a friend or colleague would benefit, please share this with them! ♻️

(You can also reach out to me on LinkedIn)

MINOR HOUSEKEEPING
How these updates are formatted

The newsletter is split into three main sections:

• THE GOOD - good news (eg. fundraises, product approvals)

• THE BAD - negative news (eg. clinical trial failures, layoffs)

• THE UGLY - negative but atypical news (lawsuits, product recalls, scandals)

Within each of the three above parts, there are additional sections for easier navigation:

• Eg. There will be multiple “The Good” sections covering things like Fundraises, Approvals, Partnerships etc.

• There will be also additional tags within these sections (Eg. fundraises may mention Stage, product approvals may mention drug name and disease area.)

See something you want to get into further? Click the Read More (goes out to either a news article or a press release).

One last thing; I know paywalls can be annoying, so there’s a [Paywall] tag for any news stories behind one.

ENJOYING THESE NEWSLETTERS?
Consider an optional paid subscription.

TLDR Biotech is currently a one-person show that works full-time to put together these compilations and related content.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

THE GOOD
Approvals & Labels

Guardant Health’s colon/rectal blood test submitted to FDA for approval
Diagnostics, blood test, cancer - Read more

THE GOOD
Business Development

AstraZeneca’s licensing deal with Nona Biosciences
$19M upfront, 10M biobucks
Antibody, cancer - Read more [Paywall]

THE GOOD
Company Launches

Hornet Therapeutics makes a buzz to tackle EBV-driven pathologies
Small molecule, Epstein-Barr Virus - Read more

THE GOOD
Fundraises

Theradaptive undisclosed funding from the Maryland Stem Cell Research Fund
Regenerative medicine, stem cells, therapeutics implants - Read more

Radar Therapeutics $13.4M Seed
RNA, drug delivery, programmable medicines - Read more

Grey Wolf Therapeutics €46M ($50M) Series B expansion
Antigen modulation, cancer, autoimmune - Read more

Bicycle Therapeutics $555M Private Equity Placement
Peptides, cancer - Read more

Cytokinetics $575M funding deal with Royalty Pharma (although it’s money so “good”, investors aren’t happy)
Small molecule, heart failure - Read more

XGEN Venture €160M ($173M) first life science fund
Venture capital - Read more

SR One $200M+ third fund
Venture capital - Read more [Paywall]

THE GOOD
Lawsuits

Biden sides with Big Pharma regarding federal appeals court verdict
Anti-Terrorism, Supreme Court - Read more

THE GOOD
Mergers & Acquisitions

Orna Therapeutics snaps up ReNAgade Therapeutics
Financial terms not disclosed
RNA, drug delivery - Read more

THE GOOD
Partnerships

Takeda, Degron Therapeutics sign $1.2B biobucks partnership
Molecular glue, oncology - Read more

Roche, Abu Dhabi collab on rare spinal disease data collection
Spinal muscular atrophy, Duchenne’s - Read more

SPONSORED
Looking to leave the lab and get into sales?

One of the biggest hurdles to overcome in this job market is experience - and the next best thing you can do is get certified in life sciences sales skills.

Succession is running a 4-week “Welcome to Sales Accelerator” to give you the skills you need and help you land your first sales role. Ready to launch your life science sales career? (Spots are filling up for the June cohort.)

Use discount code WELCOMETOSALESTLDR for $100 off!

THE GOOD
Patient Access

Teva’s Adderall no longer in short supply
Small molecule, ADHD, drug supply shortages - Read more

THE GOOD
Product Launches

Twin Health’s weight loss app, aims to reduce GLP-1 usage
Obesity, GLP-1, digital therapeutics - Read more

THE GOOD
Regulatory

European Commission releases new joint clinical assessments rules
Clinical assessment, therapeutic approval - Read more

THE GOOD
Research

Palisade Bio touts positive UC animal studies
Small molecules, ulcerative colitis - Read more

THE GOOD
Strategic Plans

Owkin unveils AI-driven drug pipeline
Small molecule, cancer - Read more

THE BAD
Clinical Trials

There are more cancer trial sites, but quality is suffering
Clinical trial management - Read more

Music stops for Tango Therapeutics’ cancer drug due to liver toxicity
Small molecule, cancer - Read more

THE UGLY
Lawsuits

Sanofi, Bristol Myers Squibb ordered to pay $916M to Hawaii, Plavix suit
Blood thinner, drug metabolism - Read more

J&J Talc saga continues, this time with accusations of “fraudulent maneuvers“
Talc, class-action, cancer - Read more

THE UGLY
Politics and Policy

US senator calls for crackdown on fraudulent Affordable Care Act enrolments - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣 

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Want to sponsor this newsletter and reach an audience of 150+ biotech and pharma professionals? Reach us here. 👍

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here.